Dalzanemdor
| Dalzanemdor | |
|---|---|
| Dalzanemdor.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Dalzanemdor is a pharmaceutical drug that acts as a selective serotonin reuptake inhibitor (SSRI). It is primarily used in the treatment of major depressive disorder and other anxiety disorders.
Mechanism of Action[edit]
Dalzanemdor functions by inhibiting the reuptake of serotonin in the synaptic cleft, thereby increasing the availability of serotonin in the central nervous system. This action is believed to contribute to its antidepressant and anxiolytic effects.
Pharmacokinetics[edit]
Dalzanemdor is administered orally and is well absorbed from the gastrointestinal tract. It undergoes extensive hepatic metabolism, primarily through the cytochrome P450 enzyme system. The drug has a half-life of approximately 24 hours, allowing for once-daily dosing.
Clinical Uses[edit]
Dalzanemdor is indicated for the treatment of:
Side Effects[edit]
Common side effects of Dalzanemdor include:
Less common but serious side effects may include:
- Serotonin syndrome
- Suicidal thoughts in young adults
Contraindications[edit]
Dalzanemdor is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should not be used in conjunction with monoamine oxidase inhibitors (MAOIs) due to the risk of serotonin syndrome.
